| scholarly article | Q13442814 |
| P50 | author | Ronald A. DePinho | Q7364619 |
| Cameron Brennan | Q30502649 | ||
| Frank B Furnari | Q56528881 | ||
| Terrance G Johns | Q57416291 | ||
| Maria-del-Mar Inda | Q125312125 | ||
| P2093 | author name string | Pamela Tan | |
| Yoshitaka Narita | |||
| Akitake Mukasa | |||
| Scott Vandenberg | |||
| Dinah W Y Sah | |||
| Philipp Hadwiger | |||
| Robert Bachoo | |||
| Rudy Bonavia | |||
| Webster Cavenee | |||
| P2860 | cites work | Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells | Q24317507 |
| Principles of interleukin (IL)-6-type cytokine signalling and its regulation | Q24530173 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme | Q27824801 | ||
| Malignant astrocytic glioma: genetics, biology, and paths to treatment | Q29618156 | ||
| Molecular characterization of the tumor microenvironment in breast cancer | Q31095898 | ||
| Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth | Q33674790 | ||
| The WHO classification of tumors of the nervous system | Q33845646 | ||
| Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. | Q33973463 | ||
| Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission | Q34226003 | ||
| Malignant glioma: genetics and biology of a grave matter. | Q34272357 | ||
| Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma | Q34655394 | ||
| Using mice to decipher the molecular genetics of brain tumors | Q35207670 | ||
| A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice | Q35211546 | ||
| A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity | Q35660849 | ||
| Advances in the biology of astrocytomas | Q35948857 | ||
| Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours | Q35994127 | ||
| Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases | Q36097402 | ||
| Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis | Q37110115 | ||
| Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis | Q37115208 | ||
| Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas | Q37174303 | ||
| Oncogenic EGFR signaling networks in glioma | Q37593841 | ||
| The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling | Q38349130 | ||
| Multiple forms of human interleukin-6. Phosphoglycoproteins secreted by many different tissues | Q38647609 | ||
| A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo | Q39866142 | ||
| Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation | Q39867455 | ||
| Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. | Q40327533 | ||
| Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme | Q40344057 | ||
| Oncostatin M signaling in human glioma cell lines | Q40438850 | ||
| Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR | Q40619097 | ||
| Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells | Q40685493 | ||
| Analysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell lines | Q40784503 | ||
| Expression of leukemia-inhibitory factor as an autocrinal growth factor in human medulloblastomas | Q40930076 | ||
| Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. | Q40997712 | ||
| Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone | Q41080169 | ||
| Human glioblastoma cells release interleukin 6 in vivo and in vitro | Q41718103 | ||
| Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage | Q41721270 | ||
| Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics | Q41885614 | ||
| Interleukin-6 gene amplification and shortened survival in glioblastoma patients. | Q42549981 | ||
| IL-6 gene amplification and expression in human glioblastomas | Q43202792 | ||
| Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. | Q45959542 | ||
| A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis | Q46091026 | ||
| Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. | Q46806113 | ||
| Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas | Q47357523 | ||
| IL-6 is required for glioma development in a mouse model | Q47817716 | ||
| Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells | Q48105086 | ||
| Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. | Q48191873 | ||
| Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis | Q48602251 | ||
| TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma | Q48673261 | ||
| Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma | Q49068065 | ||
| Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. | Q55466614 | ||
| Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. | Q55471514 | ||
| Interleukin-6 overexpression as a marker of malignancy in human gliomas. | Q55474696 | ||
| All trans-retinoic acid suppresses in vitro growth and down-regulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. | Q55475262 | ||
| An implantable guide-screw system for brain tumor studies in small animals. | Q55476199 | ||
| Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. | Q55478203 | ||
| A possible growth factor role of IL-6 in neuroectodermal tumours. | Q55479057 | ||
| Epidermal growth factor receptor and Ink4a/Arf | Q57277079 | ||
| The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization | Q62746688 | ||
| Activation of stat3 and stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines | Q73515617 | ||
| P433 | issue | 16 | |
| P921 | main subject | glioblastoma | Q282142 |
| heterogeneity | Q928498 | ||
| P304 | page(s) | 1731-1745 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | Genes & Development | Q1524533 |
| P1476 | title | Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma | |
| P478 | volume | 24 |
| Q38798587 | A Synthetic Polymer Scaffold Reveals the Self-Maintenance Strategies of Rat Glioma Stem Cells by Organization of the Advantageous Niche |
| Q46093038 | A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. |
| Q36843748 | A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression |
| Q38797345 | A comprehensive profile of recurrent glioblastoma |
| Q27324733 | A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma |
| Q60922339 | A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity |
| Q91405079 | A new model isolates glioblastoma clonal interactions and reveals unexpected modes for regulating motility, proliferation, and drug resistance |
| Q27853118 | A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study |
| Q39169154 | A population genetics perspective on the determinants of intra-tumor heterogeneity |
| Q52716114 | A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma. |
| Q39619712 | A therapeutic target for smoking-associated lung cancer |
| Q37038472 | AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors |
| Q62746702 | Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response |
| Q36852167 | Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. |
| Q36910400 | Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma |
| Q30417011 | Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch |
| Q37672593 | An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. |
| Q33665884 | An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. |
| Q38096235 | An evolutionary perspective on chronic myelomonocytic leukemia. |
| Q92441321 | Analysis of peritumoral hyperintensity on pre-operative T2-weighted MR images in glioblastoma: Additive prognostic value of Minkowski functionals |
| Q34120472 | Antibody-based immunotherapy for malignant glioma |
| Q39243060 | Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma |
| Q37601425 | Aptamer identification of brain tumor-initiating cells |
| Q35804765 | Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells |
| Q36478699 | Associating spatial diversity features of radiologically defined tumor habitats with epidermal growth factor receptor driver status and 12-month survival in glioblastoma: methods and preliminary investigation |
| Q42330185 | Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras |
| Q89351018 | Biologically Relevant Heterogeneity: Metrics and Practical Insights |
| Q41809872 | Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen |
| Q37952245 | Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas |
| Q36823916 | Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas |
| Q38941602 | C/EBPβ promotes angiogenesis through secretion of IL-6, which is inhibited by genistein, in EGFRvIII-positive glioblastoma |
| Q89121167 | Cancer cells copy migratory behavior and exchange signaling networks via extracellular vesicles |
| Q34321565 | Cancer heterogeneity: implications for targeted therapeutics |
| Q37986999 | Cancer immunoediting in malignant glioma |
| Q33779029 | Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma. |
| Q37362563 | Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. |
| Q57173826 | Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance |
| Q26852366 | Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies |
| Q60221474 | Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma |
| Q39539196 | Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation |
| Q43376098 | Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. |
| Q38943125 | Clonal cooperativity in heterogenous cancers |
| Q27027655 | Clonal evolution in hematological malignancies and therapeutic implications |
| Q36256948 | Clonal status of actionable driver events and the timing of mutational processes in cancer evolution |
| Q39160992 | Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma |
| Q42132677 | Co-survival of the fittest few: mosaic amplification of receptor tyrosine kinases in glioblastoma |
| Q57456667 | Combination therapy to checkmate Glioblastoma: clinical challenges and advances |
| Q37174174 | Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. |
| Q39149971 | Control of gp130 expression by the mitogen-activated protein kinase ERK2. |
| Q28087306 | Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma |
| Q26740256 | DNA repair mechanisms and their clinical impact in glioblastoma |
| Q52714487 | De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. |
| Q38739262 | Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model |
| Q42849220 | Deregulated expression of TANK in glioblastomas triggers pro-tumorigenic ERK1/2 and AKT signaling pathways. |
| Q35862636 | Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. |
| Q37896429 | Development and maintenance of cancer stem cells under chronic inflammation |
| Q35612289 | Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms |
| Q36438839 | Developmental Insights into Breast Cancer Intratumoral Heterogeneity |
| Q34989115 | Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation |
| Q35967385 | Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors |
| Q89555495 | Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading |
| Q35566228 | Drosophila melanogaster as a model system for human brain cancers |
| Q36042421 | Dual Receptor-Targeted Theranostic Nanoparticles for Localized Delivery and Activation of Photodynamic Therapy Drug in Glioblastomas. |
| Q35910268 | Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. |
| Q42371599 | EGF stimulates glioblastoma metastasis by induction of matrix metalloproteinase-9 in an EGFR-dependent mechanism |
| Q26853549 | EGFR Amplification and Glioblastoma Stem-Like Cells |
| Q39383476 | EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment |
| Q55460776 | EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. |
| Q41490623 | EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines |
| Q40089704 | EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. |
| Q58605925 | EGFR cooperates with EGFRvIII to recruit macrophages in glioblastoma |
| Q48014727 | EGFR heterogeneity and implications for therapeutic intervention in glioblastoma |
| Q39321309 | EGFR inhibitor BIBU induces apoptosis and defective autophagy in glioma cells |
| Q24338526 | EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma |
| Q34117589 | EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis |
| Q31062214 | EGFR soluble isoforms and their transcripts are expressed in meningiomas. |
| Q34016908 | EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing |
| Q36720916 | EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma |
| Q38199643 | EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. |
| Q64120766 | EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma |
| Q37618652 | EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. |
| Q36510801 | EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway |
| Q89848700 | EGFRvIII: An Oncogene with Ambiguous Role |
| Q42367951 | EGFRvIII: the promiscuous mutation |
| Q37400092 | EXPANDS: expanding ploidy and allele frequency on nested subpopulations |
| Q37025105 | Emerging immunotherapies for glioblastoma |
| Q35914897 | Emerging insights into the molecular and cellular basis of glioblastoma |
| Q36502009 | Emerging targets for glioblastoma stem cell therapy |
| Q55456636 | Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. |
| Q50100856 | Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies |
| Q34391942 | Epidermal growth factor receptor and variant III targeted immunotherapy. |
| Q38098098 | Epidermal growth factor receptor as a therapeutic target in glioblastoma |
| Q36977684 | Epidermal growth factor receptor targeting and challenges in glioblastoma |
| Q39121775 | Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. |
| Q38212394 | Erlotinib: early clinical development in brain cancer |
| Q26801710 | Evolutionary determinants of cancer |
| Q37276702 | Evolutionary etiology of high-grade astrocytomas |
| Q38734366 | Evolving Molecular Genetics of Glioblastoma |
| Q90750956 | Extracellular Vesicles as Conduits of Non-Coding RNA Emission and Intercellular Transfer in Brain Tumors |
| Q38781015 | Extracellular Vesicles in Brain Tumor Progression |
| Q41548598 | Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer |
| Q34625129 | Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours |
| Q91831631 | Extracellular vesicles containing oncogenic mutant β-catenin activate Wnt signalling pathway in the recipient cells |
| Q33643498 | Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. |
| Q60547811 | From Molecular to Clinical Radiation Biology of Glioblastoma |
| Q37157385 | From the Cover: Neutralization of terminal differentiation in gliomagenesis |
| Q36607541 | Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DD |
| Q37694758 | GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity |
| Q57048305 | Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors |
| Q83791245 | Genetic heterogeneity and cancer drug resistance |
| Q37838362 | Genetic modeling of gliomas in mice: new tools to tackle old problems |
| Q49678076 | Genomic alterations of ERBB receptors in cancer: clinical implications |
| Q38330237 | Genomic discoveries in adult astrocytoma |
| Q37339132 | Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes |
| Q50076163 | Glioblastoma Stem Cells and Their Microenvironment |
| Q33674388 | Glioblastoma cellular architectures are predicted through the characterization of two-cell interactions |
| Q40116157 | Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. |
| Q38182805 | Glioblastoma multiforme: a look inside its heterogeneous nature |
| Q38460865 | Glioblastoma: pathology, molecular mechanisms and markers |
| Q37491359 | Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. |
| Q41854202 | Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein |
| Q38795844 | HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies. |
| Q36750721 | Has the survival of patients with glioblastoma changed over the years? |
| Q35050894 | Heterogeneity maintenance in glioblastoma: a social network |
| Q27013006 | Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma |
| Q39116957 | High-grade serous ovarian cancer: the clone wars. |
| Q38030603 | Hotspot oncomutations: implications for personalized cancer treatment. |
| Q46581912 | Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors |
| Q34405506 | Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. |
| Q28484357 | Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment |
| Q37326086 | Identification of U251 glioma stem cells and their heterogeneous stem-like phenotypes |
| Q38790973 | Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile |
| Q97543429 | Identification of functionally distinct and interacting cancer cell subpopulations from glioblastoma with intratumoral genetic heterogeneity |
| Q28076500 | Imaging metabolic heterogeneity in cancer |
| Q35114086 | Immunotherapy for malignant glioma |
| Q38618205 | Implications of mitogen-activated protein kinase signaling in glioma. |
| Q38843843 | Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content |
| Q26795589 | Insights into Chemoresistance of Prostate Cancer |
| Q39187306 | Insights into molecular therapy of glioma: current challenges and next generation blueprint |
| Q36413235 | Inter-cellular signaling network reveals a mechanistic transition in tumor microenvironment. |
| Q37574182 | Interaction-based discovery of functionally important genes in cancers |
| Q39376212 | Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. |
| Q38051761 | Interleukins in glioblastoma pathophysiology: implications for therapy. |
| Q34687012 | Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. |
| Q26783055 | Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment |
| Q24598678 | Intratumor heterogeneity: evolution through space and time |
| Q39012270 | Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals |
| Q60300694 | Intratumoral heterogeneity of endogenous tumor cell invasive behavior in human glioblastoma |
| Q35779256 | Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response |
| Q34395869 | Ionizing radiation induces stemness in cancer cells |
| Q91994257 | Large and small extracellular vesicles released by glioma cells in vitro and in vivo |
| Q38829322 | Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses |
| Q28543966 | Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics |
| Q26797495 | Ligand-Independent EGFR Signaling |
| Q36478122 | LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets |
| Q35144727 | Long-term cultured human neural stem cells undergo spontaneous transformation to tumor-initiating cells |
| Q37604331 | Low Incidence along with Low mRNA Levels of EGFRvIII in Prostate and Colorectal Cancers Compared to Glioblastoma |
| Q35146816 | Micro-environment causes reversible changes in DNA methylation and mRNA expression profiles in patient-derived glioma stem cells |
| Q35011051 | Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (β-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. |
| Q92628156 | Molecular Biomarkers of Brain and Spinal Cord Astrocytomas |
| Q26822717 | Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date |
| Q37555785 | Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms |
| Q33945991 | Multiplicity: an organizing principle for cancers and somatic mutations |
| Q92277735 | Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas |
| Q36920373 | Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth. |
| Q30361219 | Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. |
| Q34287934 | Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity |
| Q41321306 | Non-cell-autonomous effects yield lower clonal diversity in expanding tumors. |
| Q37826349 | Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors |
| Q37695228 | Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. |
| Q35023279 | Novel points of attack for targeted cancer therapy |
| Q93369543 | Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells |
| Q37013289 | Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells |
| Q36193774 | Oncogenic extracellular vesicles in brain tumor progression |
| Q37192269 | Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch |
| Q39434238 | Organotypic explant culture of glioblastoma multiforme and subsequent single-cell suspension. |
| Q35828426 | Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition |
| Q37729676 | Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge |
| Q35779193 | Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis |
| Q30393905 | Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells |
| Q92436994 | Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma |
| Q36020891 | Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity |
| Q37208166 | Pre-diagnostic serum levels of EGFR and ErbB2 and genetic glioma risk variants: a nested case-control study |
| Q37654601 | Preclinical evaluation of radiosensitizing activity of Pluronic block copolymers |
| Q38262620 | Prioritizing targets for precision cancer medicine |
| Q92544093 | Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma |
| Q30275479 | Quantitative Analysis of the Cellular Microenvironment of Glioblastoma to Develop Predictive Statistical Models of Overall Survival |
| Q38799782 | Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution |
| Q38722183 | Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates |
| Q37721543 | Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results |
| Q36173696 | Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings. |
| Q38765346 | RareVar: A Framework for Detecting Low-Frequency Single-Nucleotide Variants |
| Q93009792 | Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk |
| Q50071181 | Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry |
| Q39456851 | Re-Evaluating Clonal Dominance in Cancer Evolution |
| Q38398440 | ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. |
| Q38905187 | Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults |
| Q41022992 | Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges. |
| Q39460640 | Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic |
| Q52663432 | Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. |
| Q93056224 | Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence |
| Q38671957 | STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications |
| Q38226313 | STAT3 in Cancer-Friend or Foe? |
| Q98289192 | STAT3-PTTG11 abrogation inhibits proliferation and induces apoptosis in malignant glioma cells |
| Q36672321 | Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation |
| Q92923704 | Share, but unequally: a plausible mechanism for emergence and maintenance of intratumour heterogeneity |
| Q38960961 | Signal Peptide Peptidase, Encoded by HM13, Contributes to Tumor Progression by Affecting EGFRvIII Secretion Profiles in Glioblastoma |
| Q26775754 | Single-cell analysis tools for drug discovery and development |
| Q38218129 | Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. |
| Q35721585 | Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion |
| Q30993492 | Spatial Habitat Features Derived from Multiparametric Magnetic Resonance Imaging Data Are Associated with Molecular Subtype and 12-Month Survival Status in Glioblastoma Multiforme |
| Q37626436 | Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity |
| Q36494583 | T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status |
| Q35802983 | Targeted therapy against cancer stem cells |
| Q33725972 | Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. |
| Q38033243 | Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells |
| Q37981764 | Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. |
| Q36297064 | Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. |
| Q93163668 | Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring |
| Q42602597 | Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. |
| Q48479118 | Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells |
| Q39071403 | The Cellular Origin and Evolution of Breast Cancer |
| Q38743781 | The Effect of Molecular Diagnostics on the Treatment of Glioma |
| Q92354027 | The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells |
| Q50201202 | The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres. |
| Q41364759 | The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells |
| Q38254181 | The cancer stem cell hypothesis: a guide to potential molecular targets |
| Q29615848 | The causes and consequences of genetic heterogeneity in cancer evolution |
| Q27015045 | The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered |
| Q38429699 | The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells |
| Q39396381 | The expression of calcitonin receptor detected in malignant cells of the brain tumour glioblastoma multiforme and functional properties in the cell line A172. |
| Q38604664 | The mini-driver model of polygenic cancer evolution |
| Q48285231 | The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells. |
| Q36795940 | The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence |
| Q28069049 | The role of tumor microenvironment in therapeutic resistance |
| Q33913152 | The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome |
| Q28300185 | The somatic genomic landscape of glioblastoma |
| Q38172182 | Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks |
| Q34154786 | Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms |
| Q39044141 | Toward Personalized Targeted Therapeutics: An Overview |
| Q102075298 | Transient commensal clonal interactions can drive tumor metastasis |
| Q39228039 | Tumor Vaccines for Malignant Gliomas |
| Q39007635 | Tumor evolution: Linear, branching, neutral or punctuated? |
| Q39246718 | Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? |
| Q35795835 | Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design |
| Q35055173 | Tumor-specific chromosome mis-segregation controls cancer plasticity by maintaining tumor heterogeneity |
| Q38544200 | Tumorigenesis: it takes a village |
| Q33731292 | Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers |
| Q26866803 | Tumour heterogeneity and the evolution of polyclonal drug resistance |
| Q98165954 | Tunneling nanotubes: A bridge for heterogeneity in glioblastoma and a new therapeutic target? |
| Q35796886 | Understanding cancer stem cell heterogeneity and plasticity. |
| Q38151582 | Using the molecular classification of glioblastoma to inform personalized treatment |
| Q38649987 | Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas. |
| Q35086702 | hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence |
| Q30419258 | miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma |
| Q48552243 | p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. |
Search more.